Concord Biotech is a biotechnology company and a leading maker of select fermentation-based APIs across immunosuppressants and oncology in ...

Concord Biotech is a biotechnology company and a leading maker of select fermentation-based APIs across immunosuppressants and oncology in ...

Analysts are of the opinion that a market premium of over 15% on the issue price is justified based on the company's business model, which ...

On the allotment date, investors get to know about the number of shares allotted to them as against the bids made. They can check the allot...

The total number of shares available for subscription stood at 14,650,957, and the share bids received around this time stood at 17,847,340...

The issue of SBFC Finance comprises fresh equity issue of Rs 600 crore and an offer for sale (OFS) of Rs 425 crore, while Concord Biotech i...

The non-institutional investors (NII) category was subscribed the most at 1.01 times, followed by retail investors at 72%. The category for...

Analysts advised investors to subscribe to Concord Biotech IPO given its complex product portfolio, presence in niche space, strong client ...

ET Intelligence Group: Ahmedabad-based Concord Biotech is a global supplier of bio-pharmaceutical APIs and formulations, serving more than ...

The initial public offering (IPO) of Concord Biotech will open for subscription on August 4. The issue closes on August 8. The company's sh...

According to the draft papers, Concord Biotech's IPO is entirely an offer for sale of (OFS) of 2,09,25,652 equity shares by Helix Investmen...

The company is backed by Quadria Capital Fund and Rare Enterprises, which was set up by billionaire investor Rakesh Jhunjhunwala, along wit...

Sources told ET that the IPO would be of ₹2000 crore - ₹2500 crore size.The issue with a face value of ₹1 per equity share is a complete of...

As per an F&S report, Concord Biotech commands a market share of over 20 per cent by volume in 2021 across identified fermentation-based AP...

Private equity firm Quadria Capital has concluded a Rs 475.31 crore investment in biopharmaceutical active ingredient manufacturer Concord ...

Ahmedabad-based Concord Biotech will invest $20 million in setting up a fermentation facility abroad to save on power and fuel costs.

World’s second-largest generic drug maker Mylan, which held a majority stake in Ahmedabad-based Concord Biotech through its subsidiary Matr...